Biological profile of adult patients infected with HIV at initiation of antiretroviral therapy in Togo;Profil biologique des patients adultes infectés par le VIH à l'initiation du traitement antirétroviral au Togo

Medecine et Maladies Infectieuses

Volumn 41, Issue 5, 2011, Pages 229-234

  Mouhari Toure, A ^a   Patassi, A ^a   Nabroulaba, K T ^b   Djadou, K E ^c   Edou, K ^c   Nyametso, D ^d   Aho, K ^a   Saibou A ^b   Kombate M ^e   Kpanla, K ^f   Niman, K W ^g   Togbossi, A ^g   Agodomou, E ^h   Wotogbe, A ⁱ   Tadona, M ^j   Singo, A ^a   Deku K ^a   Pitche, P ^a  

^a UNIVERSITÉ DE LOMÉ   (Togo)

^b Centre hospitalier universitaire de Kara   (Togo)

^c Centre hospitalier régionale de Tsévié   (Togo)

^d Centre hospitalier régionale d'Atakpamé   (Togo)

^e Centre hospitalier préfectoral d'Aného   (Togo)

^f Centre hospitalier préfectoral de Kpalimé   (Togo)

^g Centre hospitalier régionale de Sokodé   (Togo)

^h ESSOFA   (Togo)

ⁱ Centre hospitalier préfectoral de Bassar   (Togo)

^j Centre hospitalier régionale de Dapaong   (Togo)

more..

Author keywords

CD4; HAART; PLHIV; Togo

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CREATININE; HEMOGLOBIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTRANSAMINASEMIA; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; RETROSPECTIVE STUDY; THERAPY DELAY; TOGO;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES; TOGO;

EID: 79955807333     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2010.11.007     Document Type: Article

References (21)

1. Programme Commun des Nations Unies sur le VIH/SIDA (ONUSIDA). Le point sur l'épidémie de sida. Génève: ONUSIDA/OMS; 2009.
2. Programme National de Lutte contre le Sida (PNLS-Togo). PNLS-Info; 2009, 6. http://www.pnls.tg/.
3. Programme National de Lutte contre le Sida (PNLS-Togo). Guide national de prise en charge médicale de l'infection à VIH de l'adulte et de l'adolescent. Octobre 2007, 95 pages. http://www.pnls.tg/.
4. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Génève; November 30, 2009, p. 32.
5. Zannou D.M., Kindé-Gazard D., Vigan J., Adè G., Sèhonou J.J., Atadokpèdé F., et al. Profil clinique et immunologique des patients infectés par le VIH dépistés à Cotonou, Bénin. Med Mal infect 2004, 34:225-228.
6. Bashi J., Balestre E., Messou E., Maiga M., Coffie P.A., Zannou D.M., et al. Évolution des conditions d'initiation du traitement antirétroviral des patients infectés par le VIH en Afrique de l'Ouest. Med Mal Infect 2010, 40:449-455.
7. Jain V., Deeks S.G. When to start antiretroviral therapy. Curr HIV/AIDS Rep 2010, 7:60-68.
8. Braitstein P., Brinkhof M.W., Dabis F., Schechter M., Boulle A., Miotti P., et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817-824.
9. Munderi P. When to start antiretroviral therapy in adults in low-income and middle-income countries: science and practice. Curr Opin HIV AIDS 2010, 5:6-11.
10. DeSilva M.B., Merry S.P., Fischer P.R., Rohrer J.E., Isichei C.O., Cha S.S. Youth, unemployment, and male gender predict mortality in AIDS patients started on HAART in Nigeria. AIDS Care 2009, 21:70-77.
11. Kitahata M.M., Gange S.J., Abraham A.G., Merriman B., Saag M.S., Justice A.C., et al. Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. N Engl J Med 2009, 360:1815-1826.
12. Zon L.I., Arkin C., Groopman J.E. Haematologic manifestations of human immune deficiency virus (HIV). B J Hematol 1987, 66:251-256.
13. Mugisha J.O., Shafer L.A., Van der Paal L., Mayanja B.N., Eotu H., Hughes P., et al. Anaemia in a rural Ugandan HIV cohort: prevalence at enrolment, incidence, diagnosis and associated factors. Trop Med Int Health 2008, 13:788-794.
14. Warrell D.A., Cox T.M., Firth J.D., Benz E.J. The complex and multiple aetiology of anemia in the third world. Oxford text book of medicine 2003, vol. 3:p. 645 ff. Oxford University Press, Inc, New York, Ch. 22. 4th edn.
15. Diallo D.A., Baby M., Dembele M., Kéita A., Sidibé A.T., Cissé I.A., et al. Frequency, risk factors and prognostic value of anaemia associated with HIV/AIDS in adults In Mali. Bull Soc Pathol Exot 2003, 96:123-127.
16. Fangman J.J., Scadden D.T. Anemia in HIV-infected adults: epidemiology, pathogenesis, and clinical management. Curr Hematol Rep 2005, 4:95-102.
17. Jam S., Ramezani A., Sabzvari D., Moradmand-Badie B., Seyedalinaghi S., Jabbari H., et al. A cross-sectional study of anemia in human immunodeficiency virus-infected patients in iran. Arch Iran Med 2009, 12:145-150.
18. Anglaret X., Chêne G., Attia A., Toure S., Lafont S., Combe P., et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 1999, 353:1463-1468.
19. Sabin C.A. Pitfalls of assessing hepatotoxicity in trials and observational cohorts. Clin Infect Dis 2004, 38(Suppl. 2):S56-S64.
20. Mata-Marín J.A., Gaytán-Martínez J., Grados-Chavarría B.H., Fuentes-Allen J.L., Arroyo-Anduiza C.I., Alfaro-Mejía A. Correlation between HIV viral load and aminotransferases as liver damage markers in HIV infected naive patients: a concordance cross-sectional study. Virol J 2009, 6:181.
21. Kovari H., Ledergerber B., Battegay M., Rauch A., Hirschel B., Foguena A.K., et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection. Clin Infect Dis 2010, 50:502-511.